AMCP Annual 2025 research posters

Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model
Click on the poster image to view the full-size version.
Prime Therapeutics (Prime) once again has a robust presence at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting in Houston from March 31–April 3. AMCP is the nation’s leading professional association that aims to help patients get the medications they need at a cost they can afford. This event annually attracts more than 4,000 industry leaders, health care professionals and stakeholders committed to advancing the field. Prime’s teams will present research posters and educational sessions on health outcomes research.  

Two-Year Persistent Glucagon-Like Peptide-1 Agonist Obesity Without Diabetes Treatment: Clinical Outcomes Among Commercially Insured

This study compares changes in clinical outcomes one year before and the second year after GLP-1 obesity treatment initiation among commercially insured members without diabetes.

Real-World 2-Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Without Diabetes Among a Commercially Insured Population

This study describes changes in annual total cost of care (TCC) one year before and two years after GLP-1 obesity treatment initiation among commercially insured members without diabetes.

Two-Year Persistent Glucagon-Like Peptide-1 Agonist Obesity Without Diabetes Treatment: Cost-Effectiveness Among Commercially Insured

This study identifies changes in annual TCC one year before and two years after GLP-1 obesity treatment initiation among commercially insured members without diabetes who were persistent to therapy.

Real-World 2-Year Clinical Outcomes Following Initiation of Glucagon-Like Peptide-1 Agonists to Treat Obesity Without Diabetes Among a Commercially Insured Population

This study examines changes in clinical outcomes one year before and two years after GLP-1 obesity treatment initiation among commercially insured members without diabetes.

Medicare Member Drug Cost Predictive Model: Creation and Feature Engineering 

The recipient of a silver award, this study creates a predictive model to identify members enrolled in Medicare Part D who were at risk of large increases in prescription drug spending over a 12-month period. 

Resident research posters

Medication Adherence in Myasthenia Gravis: Exploring Patient Characteristics and Treatment

This study explores medication adherence in patients with myasthenia gravis (MG), a chronic autoimmune disease that causes muscle weakness. 

Treatment Journey of Age-Related Macular Degeneration and Diabetic Macular Edema Patients: Analyzing Bevacizumab Persistence and Therapy Switching

This study examines the persistence and therapy switching of patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) treated with bevacizumab (Avastin®). 

Login Portals
Compliance / Legal
Careers
© 2025 Prime Therapeutics LLC